Document is current
Any future updates will be listed below
-
Authors
Andreano, Emanuele https://orcid.org/0000-0003-0088-5788
Paciello, Ida
Pierleoni, Giulio
Maccari, Giuseppe https://orcid.org/0000-0002-2894-3583
Antonelli, Giada
Abbiento, Valentina https://orcid.org/0000-0002-4804-1739
Pileri, Piero https://orcid.org/0000-0002-2888-8748
Benincasa, Linda
Giglioli, Ginevra
Piccini, Giulia https://orcid.org/0000-0001-8090-7910
De Santi, Concetta
Sala, Claudia
Medini, Duccio
Montomoli, Emanuele
Maes, Piet https://orcid.org/0000-0002-4571-5232
Rappuoli, Rino https://orcid.org/0000-0002-8827-254X
- License Information
-
More Information
Article History
Received: 4 August 2022
Accepted: 16 March 2023
First Online: 28 March 2023
Competing interests
: E.A., I.P., V.A., P.P., C.D.S., C.S., and R.R. are listed as inventors of full-length human monoclonal antibodies described in Italian patent applications n. 102020000015754 filed on June 30th 2020, 102020000018955 filed on August 3rd 2020 and 102020000029969 filed on 4th of December 2020, and the international patent system number PCT/IB2021/055755 filed on the 28th of June 2021. All patents were submitted by Fondazione Toscana Life Sciences, Siena, Italy. Remaining authors have no competing interests to declare.
